自行注射免疫療法：產品、療法、市場和策略

Self-administered Injectable Immune Therapeutics, Products, Therapeutics, Markets & Strategies

出版日期: 2024年01月17日 | 出版商:

Greystone Research Associates | 英文 250 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

在抗體藥物及其候選藥物激增的推動下，生物製劑在開發管道和臨床試驗中繼續超過所有其他新化學實體。這種從小分子藥物的轉變正在為藥物開發商、醫療器材設計師、包裝商甚至藥物行銷人員創造商機。

由於生物製劑通常針對慢性疾病，因此必須制定長期使用的劑量策略和治療方案，並且往往受到與醫療狀況直接相關的潛在限制，必須制定供某些患者自行注射的方案。未來五年，隨著藥物開發商應對越來越多的慢性病患者的需求，包裝從一次性和多用途小瓶轉向預充式註射器的轉變將會加速。抗體、荷爾蒙和其他生物製劑的強大生理作用也增加了對安全性和合規性的需求。

本報告對全球自給藥注射免疫治療市場進行了分析，並概述了產品、主要類型、市場基本結構、主要驅動和限制因素以及主要公司的未來前景（截至2028年）。開發策略及其影響因素，自用注射免疫治療藥物的開發和製造生態系統，以及未來產品選擇的關鍵經濟、技術和監管因素。

貼片泵浦
大容量穿戴裝置
穿戴式產品分析
Libertas (Becton Dickinson)
Patch Pump (Sensile Medical)
SmartDose (West Pharmaceuticals)
Neulasta OnPro Injector (Insulet/Amgen)
YpsoDose (Ypsomed)
電子半一次性產品
E3D Patch Pump (Elcam)
一次性機械產品
enFuse (Enable Injections)
專用設備
sc2Wear Infusor (scPharmaceuticals)
PatchPump (SteadyMed)

新技術

無線數據
重點治療領域分析
過敏反應/措施
自身免疫性疾病
類風濕關節炎
銀屑病
多發性硬化症
緊急醫療護理
肝炎
造血作用
激素
骨質疏鬆症

市場因素

監管問題
設備品牌
患者依從性和易用性
衛生經濟學
生物藥元素
供貨時的包裝
配方要素
生物給藥生態系統
技術要素
競爭格局

簡介目錄

Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic biological drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Therapeutics for Refractory Conditions

Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and - ultimately - pharmaceutical marketers.

Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.

What You Will Learn:

What are the market factors that define the therapeutic injectable immune disease market?

What are the major factors driving product development strategies within biologicals drug development organizations to 2028?

How does the availability of patient support resources influence prescribing decisions for immune drugs?

How important are drug developer-formulation technologist relationships in therapeutic market segments?

What is the current state of the global self-administered immune therapeutics development and manufacturing ecosystem?

What are the significant economic, technological, and regulatory factors affecting the selection criteria for self-administered immune therapeutics to 2028?